Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2005 02:12 ET | Source: Crucell N.V.

Galapagos NV & ASINEX Ltd. Initiate Drug Discovery Collaboration in Bone and Joint Diseases

MECHELEN, Belgium and MOSCOW, May 12, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company and ASINEX Ltd, a worldwide leader in lead generation and optimization announce that...
May 12, 2005 02:00 ET | Source: Lakefront Biotherapeutics

GALAPAGOS NV & ASINEX LTD. INITIATE DRUG DISCOVERY COLLABORATION IN BONE AND JOINT DISEASES

In the first phase of the collaboration, Galapagos' biologists will work closely with ASINEX's medicinal chemists, using ASINEX's computational chemistry expertise and proprietary chemical compound...
May 12, 2005 02:00 ET | Source: Lakefront Biotherapeutics

GALAPAGOS NV EN ASINEX LTD GAAN EEN DRUG DISCOVERY SAMENWERKING AAN IN BOT- EN GEWRICHTSZIEKTEN

In de eerste fase van de overeenkomst zullen biologen van Galapagos en medicinale scheikundigen van ASINEX samenwerken om chemische moleculen te identificeren voor de door Galapagos gepatenteerde...
March 31, 2005 05:06 ET | Source: Crucell N.V.

Crucell N.V.: Staf Van Reet to lead Galapagos Corporate Development

LEIDEN, The Netherlands, March 31, 2005 (PRIMEZONE) -- Galapagos, a genomics-based drug discovery company, announces that it has appointed Staf Van Reet as VP Corporate Development. Dr. Van Reet will...
March 09, 2005 03:18 ET | Source: Crucell N.V.

Galapagos Considering a Stock Exchange Listing

LEIDEN, The Netherlands, March 9, 2005 (PRIMEZONE) -- Galapagos Genomics NV, a genomics-based drug discovery company, announces that it is considering a Euronext stock exchange listing in 2005. The...
January 20, 2005 02:08 ET | Source: Crucell N.V.

Boehringer Ingelheim Licenses Results from Target Discovery Collaboration with Galapagos

LEIDEN, The Netherlands and MECHELEN, Belgium, Jan. 20, 2005 (PRIMEZONE) --Galapagos announced today that Boehringer Ingelheim has successfully used Galapagos' SilenceSelect(tm) gene knock-down...
November 30, 2004 02:06 ET | Source: Crucell N.V.

Graham Dixon joins Galapagos as Chief Scientific Officer

MECHELEN, Belgium and LEIDEN, The Netherlands, Nov. 30, 2004 (PRIMEZONE) -- Galapagos announced today that Graham Dixon has been appointed Chief Scientific Officer (CSO). Dr. Dixon will be...
November 18, 2004 07:10 ET | Source: Crucell N.V.

Celgene and Galapagos Enter Target Discovery Collaboration

WARREN, N.J. and MECHELEN, Belgium and LEIDEN, The Netherlands (PRIMEZONE) -- Celgene (Nasdaq:CELG), a leading global biopharmaceutical company with focus on the discovery, development and...
November 09, 2004 02:08 ET | Source: Crucell N.V.

Crucell N.V.: Wyeth Selects Novel Drug Targets in Osteoporosis Collaboration With Galapagos

LEIDEN, The Netherlands and MECHELEN, Belgium, Nov. 9, 2004 (PRIMEZONE) -- Galapagos Genomics announced today that it has reached a research milestone in its osteoporosis discovery program with Wyeth...
October 05, 2004 02:08 ET | Source: Crucell N.V.

Galapagos appoints Raj Parekh as Chairman and Wilson Totten to Board of Directors

MECHELEN, Belgium and LEIDEN, The Netherlands, Oct. 5, 2004 (PRIMEZONE) -- Galapagos Genomics NV announced that it has appointed Raj Parekh, Ph.D. as Chairman and Wilson Totten, M.D. to the company's...